Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  etoposide phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 51 for your search:
Start Over
Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 1 to 18
Trial IDs: TOT17, NCI-2017-00582, NCT03117751
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, 1407-GUCG, 2014-003930-17, PA031102_A01PAMDREVW01, NCT02375204
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756, NCT02883049
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30081, NCI-2016-01683, 2015-004861-97, NCT02763579
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 3505, NCI-2016-01976, CA209-333, RF 3505, NCT02768558
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGI-110-06, NCI-2017-00040, NCT02920008
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 0 to 49
Trial IDs: AGCT1531, NCI-2017-00178, NCT03067181
Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 21
Trial IDs: 16-001, NCI-2017-00431, NCT03020030
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 11 to 45
Trial IDs: AGCT1532, NCI-2017-00559, NCT02582697
Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D419QC00001, NCI-2017-00703, 2016-001203-23, NCT03043872
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-604, NCI-2017-00791, 2016-004309-15, NCT03066778
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 365 days to 30 years
Trial IDs: ANBL1531, NCI-2016-01734, NCT03126916
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Lenalidomide, Combination Chemotherapy, and Rituximab in Treating Patients with Primary Effusion Lymphoma or KSHV-Associated Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0171, NCI-2016-01483, P162804, NCT02911142
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1380, NCI-2016-01991, NCT02748889
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00000922, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, ONC-02019-L, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients with Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0264, NCI-2011-02000, CDR0000662814, NCT01042522
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0367, NCI-2014-01356, NCT02106988
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients with Small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9974, NCI-2016-01363, TBD, NCT02899728
RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-211-01, NCI-2016-01889, NCT02489903
Pembrolizumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: S16-01031, NCI-2017-00123, NCT02934503
Start Over